Zenosense Inc (OTCMKTS:ZENO) is making a strong move up on growing volume off the $0.24 lows the stock hit after the collapse from its $0.60 highs reached after months of a steady upward run.
ZENO recently announced an exclusive global license agreement to develop and market medical devices for use in hospitals and primary healthcare settings targeting the early detection of both deadly bacteria and certain cancers in the exhaled breath of patients.
Zenosense Inc (OTCMKTS:ZENO) currently has two devices under development; a device intended to detect the Methicillin-resistant Staphylococcus aureus “Super-Bug” (MRSA); and a device intended to detect Lung Cancer. Using a common Electronic Nose technology platform, the devices analyze Volatile Organic Compounds (VOCs) which are present in the exhaled breath of patients, scanning for certain biomarkers which can indicate the presence of infection/illness.
The Company has received significant media attention on the way up with a recent syndicated story on the Company that appeared in chrome.com and stated ”The plan is for Zenosense’s device to help medical staff determine whether MRSA and other superbugs are present in a room by embedding the device on ID badges or name badges, which are already worn by hospital staff. A warning beep or blinking light will alert the staff member, who can then contact a cleaning crew to remove the bacteria before it could potentially infect a patient.
To Find out the inside Scoop on ZENO Subscribe to Microcapdaily.com Right Now by entering your Email in the box below
These devices using scent technology to detect bacteria and lung cancer are still under development. Investors have the opportunity to become involved in supporting the development of this latest medical breakthrough, as Zenosense is a publicly traded company.”
On November 4 ZENO announced the manufacturing of a pre-commercial prototype device to be evaluated for the detection of lung cancer in exhaled breath (“Device”).
Prototyping manufacture is well advanced. The work has been undertaken by the Company’s contracted development partner Zenon Biosystem which is part of the Sgenia group. In line with the protocol design for an anticipated lung cancer detection trial to be held in a clinical setting, two pre-commercial Devices are currently being manufactured of the same design to ensure reproducibility of results. The completed Devices are expected to be ready during the second half of the current month.
These components and their elements include molecular sieves incorporated in complementary layered and mixed sensor structures to screen incoming VOCs, and nanometric sensing mesh to maximize the detective area. During this optimization process Zenon has developed new metal oxide materials and combinations of metal oxides that cannot be found in commercially available sensors.
Development work is being carried out by a team of experts in nanotechnology, sensors, high-level mathematics, molecular biology and biochemistry. Collaborations and partnerships are also in place with hospitals, universities and a private laboratory in the fields of sensors, polymer electrochemistry, microbiology, infectious disease, pneumology, chromatography and microorganism identification.
We have a Monster Pick Coming. Subscribe Right Now!
Conclusion: ZENO has made a big move up in recent months from lows of $0.15 this past summer. The stock has gone from relative obscurity to become one of the top traded stocks on the entire OTCBB. Currently trading at a $23 million market valuation the stock looks to be under accumulation here and is quickly developing the type of loyal shareholder base that can drive these bb’s skyward. The stock also benefits from significant recent media attention as well as the obvious connection between Ebola and the Company’s medical diagnostic tool using scent-detection technology currently under development.
Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!
Disclosure: we hold no position in ZENO either long or short and we have not been compensated for this article.